Manufacturers Seek More Clarity On GMP Obligations For Combo Products
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers support the gist of FDA’s draft guidance on combination product current good manufacturing practices, but they want more clarity on roles, quality requirements, design controls and stability testing, according to written comments.
You may also be interested in...
Combo Products GMP Guidance Fills In Gaps On Drug-Delivery Device Compliance
FDA has delivered a draft current good manufacturing practices guidance for combination products, providing details and examples on how the agency regulates drug delivery devices and other drug/device, drug/biological and drug/device/biological products.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.